SCHEMBL925523

SCHEMBL925523

CCc1c(-c2nnc(C3CCCCCC3)o2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.63
CNR1 P21554 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923216 1.00 CNR2 (0.63) CNR2CNR1
SCHEMBL924665 0.99 CNR2 (0.63) CNR2CNR1
SCHEMBL925298 0.97 CNR2 (0.61) CNR2CNR1
SCHEMBL4466820 0.96 CNR2 (0.63) CNR2CNR1
SCHEMBL923283 0.95 CNR2 (0.69) CNR2
SCHEMBL923357 0.95 CNR2 (0.69) CNR2
SCHEMBL923518 0.94 CNR2 (0.68) CNR2
SCHEMBL923234 0.92 CNR2 (0.68) CNR2
SCHEMBL923319 0.89 CNR2 (0.62) CNR2
SCHEMBL924340 0.89 CNR2 (0.62) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875647-B2 and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders GREEN CROSS CORPORATION (KR) 2011-01-25 US disclosed
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists CNR2, CNR1, GPR119 CNR2 1/4885CNR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.